Effects of atorvastatin and ticagrelor combination therapy on renal function and the levels of suppression of tumorigenicity 2 and interleukin-33 in patients with ST-segment elevation myocardial infarction

Li Zhang¹, Miao Hu¹, Yuan Chen² and Yijun Wang¹

Abstract

Objective: We evaluated the effects of atorvastatin and ticagrelor combination therapy on renal function and the levels of suppression of tumorigenicity 2 (ST2) and interleukin 33 (IL-33) in patients with ST-segment elevation myocardial infarction (STEMI).

Methods: Eighty-four STEMI patients who underwent emergency percutaneous coronary intervention at our hospital from January 2015 to March 2018 were retrospectively analyzed and divided into a control group (n = 44) and an observation group (n = 40). The control group was treated with atorvastatin as routine STEMI treatment, whereas the observation group was concurrently administered ticagrelor.

Results: After treatment, significantly better outcomes were observed in the control group than in the observation group in terms of clinical indices, including chest pain relief, enzyme levels, duration of reperfusion-associated arrhythmia, and depression of the ST segment. Both groups exhibited improvements in cardiac ultrasound indices, whereas the observation group showed lower left ventricular end-diastolic and end-systolic diameters and higher left ventricular ejection fractions than the control group.

Corresponding author:
Yijun Wang, Department of Pharmacy, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Email: efywyj@163.com
Conclusions: Atorvastatin and ticagrelor combination therapy is clinically effective and safe for STEMI patients as it reduces the degree of myocardial infarction, protects the heart and renal functions, improves inflammation, and reduces adverse cardiac event incidences.

Keywords
Atorvastatin, ticagrelor, combination treatment, ST-segment elevation myocardial infarction, renal function, inflammation

Date received: 21 February 2020; accepted: 26 August 2020

Introduction
ST-segment elevation myocardial infarction (STEMI) refers to a clinical condition in which the epicardial artery is completely and continuously blocked because of myocardial ischemia and blood flow truncation in the collateral branch of the coronary artery. Continuous artery blockage may result in an insufficient or even interrupted blood supply to various organs and lead to ischemic necrosis of cardiomyocytes.1,2 Recently, this condition has become increasingly prevalent among the elderly population and patients with atherosclerosis. It is a significant life-threatening health condition with high disability and fatality rates.3,4 In the early stage, reperfusion therapy is the main approach to treat stenosis and blockage of the coronary artery lumen via percutaneous coronary intervention (PCI).5,6 The effectively curative and life-saving benefits of this therapy, as well as its ability to improve the quality of life of patients, have been demonstrated in several clinical cases. Given the advantages of PCI that include treating the infarcted coronary artery, recovering myocardial perfusion, and reducing mortality, it is always the preferred treatment for patients with coronary disease. Thus, drug therapies that help avoid surgery and subsequent surgical wounds have been suggested as an alternative for STEMI treatment.7

Statins control the progression of heart failure that results from lipid metabolism disorders and regulate the endocrine secretion of response factors for heart function. Atorvastatin, a member of this family, protects endothelial cells.8,9 Ticagrelor selectively inhibits the binding of adenosine diphosphate to its receptor, thereby bypassing liver metabolism in vivo and plays a significant role in inhibiting platelet aggregation and preventing thrombus formation.10 Studies suggest that STEMI-associated myocardial damage may arise from complicated conditions or atheromatous plaque ruptures, leading to microvascular obstruction and even transient vascular occlusion or spasm. Patients with myocardial infarction may also experience acute renal failure due to improper control and treatment of the disease, and these cases account for a large proportion of hospital-acquired kidney injury patients.11 A previous study12 reported that as a significant factor inducing atherosclerosis, inflammation is closely associated with STEMI, but the levels of inflammatory markers vary during the development and progression of STEMI. Therefore, the present study aimed to investigate the effect of atorvastatin and ticagrelor combination therapy on STEMI patients by evaluating their renal function and inflammation indices.
Materials and methods

Patient characteristics
Eighty-four patients with STEMI who underwent emergency PCI at our hospital from January 2015 to March 2018 were included in this retrospective analysis and divided into the control group (n = 44) and the observation group (n = 40). Patients in the control group were treated with atorvastatin as routine STEMI treatment, whereas those in the observation group concurrently received ticagrelor. All patients and their family members signed an informed consent form and agreed to participate in the study. The study was approved by the Ethics Committee of The Second Affiliated Hospital of Nanjing Medical University.

Inclusion and exclusion criteria
Inclusion criteria were as follows: patients who had been diagnosed with STEMI based on the Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation written by the European Society of Cardiology and demonstrated to comply with the STEMI diagnosis standards in Clinical Cardiology Diagnostic Imaging and treatment indications in the Guidelines and Consensus for the Prevention and Treatment of Cardiovascular Diseases.\textsuperscript{13,14} Patients were excluded if they had received relevant treatments before this study; been suffering from concomitant organic lesions in the brain, concomitant coagulation function diseases or immunity diseases, or mental/cognitive impairment; or were lactating.

Reagents and materials
Ticagrelor was obtained from AstraZeneca Pharmaceutical Co., Ltd. (Cambridge, UK) with the approval no. H20171079, and atorvastatin calcium tablets were obtained from Pfizer Pharmaceuticals Limited (New York, NY, USA) with the approval no. H20051408. A Carotid doppler ultrasound (CDU) was obtained from Qisheng (Shanghai) Medical Device Co., Ltd. with the approval no. GXZJ20153541809, a 12-lead electrocardiogram (ECG) machine (model ECG-1350) was obtained from Jinan Shengrui Biotechnology Co., Ltd., and an automatic biochemical analyzer was obtained from Shandong Biobase Technological Instrument Co., Ltd. An enzyme-linked immunosorbent assay (ELISA) kit was obtained from Shanghai Jingkang Bioengineering Co., Ltd., and an enzyme-labeling instrument was obtained from Shanghai Yongchuang Bioengineering Co., Ltd.

Treatments
Patients in the observation group were orally administered ticagrelor at an initial dose of 180 mg and subsequent doses of 90 mg two times per day for 2 months according to routine symptomatic and thrombolytic therapies for myocardial ischemia. Patients in the control group were additionally given 80 mg of atorvastatin calcium tablets orally before thrombolytic therapy, followed by subsequent oral doses of 20 mg/day for 2 months. Atorvastatin was used in the later stage as a long-term treatment for patients with myocardial infarction.

Detection of indices
Under inactive conditions, patients laid down in a left lateral position to undergo transthoracic echocardiography via CDU to measure left ventricular end-diastolic and end-systolic diameters (LVESD and LVEDD, respectively) and left ventricular ejection fraction (LVEF). Before treatment, a routine 12-lead ECG fluctuation curve
was obtained for all patients using a 12-lead ECG machine, and the results were evaluated and analyzed using the Selvester QRS scoring system (a 54 criterion/32-score system, with each score representing 3% of the left ventricular area) to determine the myocardial infarct size.\textsuperscript{15} The renal function indices in both groups, including serum creatinine (Scr), cystatin C (Cys-C), and $\beta_2$ macroglobulin ($\beta_2$-MG) levels, were determined using an automatic biochemical analyzer. With the patients in a fasting state, 5 mL of blood were drawn from the peripheral vein and centrifuged at 3920 $\times$ g for 5 minutes to obtain the serum, which was stored at $-80^\circ$C and analyzed using an ELISA kit to determine the levels of suppression of tumorigenicity 2 (ST2) and interleukin 33 (IL-33). Standards at gradient concentrations were prepared according to the manufacturers’ instructions. The optical density (OD) was measured at a 490-nm wavelength using an enzyme-labeling instrument, and IL-33 and ST2 levels in the samples were calculated based on the standard curve. The examinations were performed after 2 months.

**Observation indices**

The two groups were observed, and changes in clinical indices, cardiac ultrasound indices (LVESD, LVEDD, and LVEF), myocardial infarct size, renal function, ST2 and IL-33 levels, clinical effects, adverse cardiovascular events, and other adverse reactions were compared before and after treatment. Clinical effects were graded as markedly effective if there was a complete improvement in angina pectoris symptoms and a rapid recovery of ECG changes and serum myocardial markers to normal levels; effective if the onset times or duration of angina pectoris were significantly reduced, ST segment on ECG dropped after treatment but failed to recover to the normal level, flat T wave transformed into a vertical shape, and myocardial marker levels recovered after a long period; and ineffective if the symptoms were not improved, ECG showed no changes, or no significant recovery was observed in myocardial marker levels.\textsuperscript{16}

**Statistical analysis**

Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 19.0 (IBM Corp., Armonk, NY, USA) for experimental data. Nominal data were tested using the chi-square test, and numerical data were expressed as means $\pm$ standard deviations. Comparison studies were conducted using a t-test between the two groups and paired t-test for pre- and post-comparisons within a group. Graphpad Prism 8 (Graphpad Software, San Diego, CA, USA) was used for drawing plots. For all statistical comparisons, significance was set at $p < 0.05$.

**Results**

**Patient characteristics**

The study participants consisted of 52 men and 32 women (mean age, 65.36 $\pm$ 9.47 years) and included cases of concomitant hypertension ($n = 55$), concomitant diabetes ($n = 36$), anterior myocardial infarction ($n = 28$), inferior wall myocardial infarction ($n = 34$), inferior and posterior wall myocardial infarction ($n = 13$), and other diseases ($n = 9$). The two groups showed no significant differences in terms of gender, age, and the presence of hypertension and diabetes (Table 1).

**Changes in clinical indices**

After treatment, significantly better outcomes were observed in the control group than in the observation group in terms of chest pain relief, enzyme levels, duration of reperfusion-associated arrhythmia, and
depression of the ST segment ($p < 0.05$; Table 2).

**Cardiac ultrasound indices**

There were no significant between-group differences in LVESD, LVEDD, and LVEF before treatment; however, significantly lower LVESD and LVEDD and higher LVEF were observed after treatment in the observation group than in the control group ($p < 0.05$, Figure 1).

**Myocardial infarct size**

There were no significant between-group differences in myocardial infarct size before treatment. The infarct size markedly decreased after treatment in both groups, with the observation group exhibiting a significant decrease ($p < 0.05$; Figure 2).

---

**Table 1.** Patient characteristics.

| Group                          | Control Group (n = 44) | Observation Group (n = 40) | $\chi^2$/t | P  |
|-------------------------------|------------------------|---------------------------|------------|----|
| Gender, n (%)                 |                        |                           | 0.011      | 0.915 |
| Male                          | 27 (61.36)             | 25 (62.50)                |            |    |
| Female                        | 17 (38.64)             | 15 (37.50)                |            |    |
| Age (year)                    | 65.19 ± 9.53           | 65.52 ± 9.38              | 0.160      | 0.874 |
| BMI (kg/m²)                   | 23.11 ± 1.12           | 23.31 ± 1.17              | 0.800      | 0.426 |
| Hypertension, n (%)           |                        |                           | 0.008      | 0.930 |
| Yes                           | 29 (65.91)             | 26 (65.00)                |            |    |
| No                            | 15 (34.09)             | 14 (35.00)                |            |    |
| Diabetes, n (%)               |                        |                           | 0.004      | 0.950 |
| Yes                           | 19 (43.18)             | 17 (42.50)                |            |    |
| No                            | 25 (56.82)             | 23 (57.50)                |            |    |
| Smoking, n (%)                |                        |                           | 0.043      | 0.836 |
| Yes                           | 13 (29.55)             | 11 (27.50)                |            |    |
| No                            | 31 (70.45)             | 29 (72.50)                |            |    |
| Infarction site, n (%)        |                        |                           | 0.259      | 0.968 |
| Anterior                      | 15 (34.09)             | 13 (32.50)                |            |    |
| Inferior wall                 | 18 (40.91)             | 16 (40.00)                |            |    |
| Inferior wall and posterior   | 7 (15.91)              | 6 (15.00)                 |            |    |
| Other                         | 4 (9.09)               | 5 (12.50)                 |            |    |
| Killip classification of heart function, n (%) |                        |                           | 0.290      | 0.962 |
| Class I                       | 19 (43.18)             | 17 (42.50)                |            |    |
| Class II                      | 13 (29.55)             | 11 (27.50)                |            |    |
| Class III                     | 9 (20.45)              | 8 (20.00)                 |            |    |
| Class IV                      | 3 (6.82)               | 4 (10.00)                 |            |    |
| Degree of stenosis (%)        | 79.45 ± 9.54           | 79.63 ± 9.72              | 0.086      | 0.932 |
| Thrombus location (n)         |                        |                           | 0.021      | 0.885 |
| Proximal blood vessel         | 27 (61.36)             | 24 (60.00)                |            |    |
| Distal vessel                 | 17 (38.64)             | 16 (40.00)                |            |    |
| Myocardial ischemic necrosis (n) |                      |                           | 0.081      | 0.776 |
| Yes                           | 25 (56.82)             | 22 (55.00)                |            |    |
| No                            | 19 (43.18)             | 18 (45.00)                |            |    |

The degree of vascular diameter stenosis was measured by the quantitative analysis of coronary angiography.

BMI, body mass index.
Figure 1. Cardiac ultrasound indices before and after treatment in STEMI patients. The control group (n = 44) and observation group (n = 40) were given oral atorvastatin (80 mg before thrombolytic therapy and subsequent doses of 20 mg/day for 2 months) or a combination of atorvastatin and ticagrelor (initial dose of 180 mg and subsequent doses of 90 mg two times per day for 2 months), respectively. (A) Both groups demonstrated a decrease in LVESD, which was significant in the observation group. (B) Both groups demonstrated a decrease in LVEDD, which was significant in the observation group. (C) Both groups demonstrated an increase in LVEF, which was significant in the observation group. The results are presented as the mean ± standard deviation, and * represents p < 0.05.

ST-segment elevation myocardial infarction, STEMI; LVESD, left ventricular end-diastolic diameter; LVEDD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction.

Table 2. Changes in clinical indices.

| Group                                      | Control Group (n = 44) | Observation Group (n = 40) | t     | P     |
|--------------------------------------------|-----------------------|---------------------------|-------|-------|
| Duration of chest pain relief (h)          | 1.47 ± 0.93           | 1.05 ± 0.84               | 2.164 | 0.033 |
| Occurrence of enzyme peak (h)              | 13.63 ± 2.67          | 10.16 ± 2.15              | 6.519 | <0.001|
| Duration of reperfusion-associated arrhythmia (h) | 1.59 ± 0.35           | 1.21 ± 0.27               | 5.531 | <0.001|
| Depression of ST segment (mV)              | 1.34 ± 0.46           | 1.02 ± 0.39               | 3.421 | 0.001 |
Renal function
There were no significant between-group differences in Scr, Cys-C, and β2-MG levels before treatment. These levels markedly decreased after treatment, with the observation group exhibiting a significant decrease (p < 0.05; Figure 3).

ST2 and IL-33 levels
There were no significant between-group differences in ST2 and IL-33 levels before treatment. These levels markedly decreased after treatment, with the observation group exhibiting a significant decrease (p < 0.05; Figure 4).

Clinical effects
The total effective rate in the control group was significantly lower than that in the observation group after treatment (p < 0.05; Table 3).

Adverse cardiovascular events and adverse reactions
After treatment, the control group exhibited a significantly higher total incidence of adverse cardiovascular events than the observation group (p < 0.05); however, no significant between-group differences were observed in the total incidence of adverse reactions (Tables 4 and 5).

Discussion
STEMI progresses rapidly and may lead to the development of coronary artery disease.17 STEMI has a poor prognosis; however, when the condition is detected early, further deterioration may be effectively prevented using thrombolytic therapy to recover blood oxygen reperfusion. Thrombolytic drugs vary in efficacy and safety.18 Atorvastatin regulates metabolism and cholesterol levels in the liver and helps recover vascular endothelial functions by selectively inhibiting the biosynthesis of cholesterol and 3-hydroxy-3-methylglutaryl coenzyme A, increasing lipoprotein receptor levels, reducing the surface density of liver cells, and decreasing lipoprotein and cholesterol levels in the body.19 In addition to suppressing platelet aggregation, ticagrelor can significantly reduce the incidence of postoperative hemorrhage.20 Previous studies have reported that together with classical stress response cytokines, IL-33 regulates cellular activity and contributes to immune response regulation.21 IL-33 transduces signals to ST2L via ST2 to induce the expression of Th2-associated cytokines, thus enhancing the inflammatory response.22
Both drugs are useful in patients with STEMI, but the clinical efficacy of their combination is seldom reported. Studies on STEMI have shown that in the advanced stage, the status of renal function and inflammatory parameters affect the prognosis. Therefore, the present study explored the effect of a combination of atorvastatin and ticagrelor on renal function and the levels of ST2 and IL-33 in patients with STEMI to elucidate the most effective therapeutic option.

Changes in clinical indices and efficacy were observed in the two groups. After treatment, the observation group showed significantly lower clinical indices and a higher total effective rate than the control group, indicating that using a combination of the two drugs improves the effects on heart function recovery and pain relief compared with atorvastatin alone. To explore the factors contributing to the enhanced drug efficacy, cardiac ultrasound indices were first analyzed. The results showed

**Figure 3.** Renal function before and after treatment in STEMI patients. The control group (n = 44) and observation group (n = 40) were given oral atorvastatin (80 mg before thrombolytic therapy and subsequent doses of 20 mg/day for 2 months) or a combination of atorvastatin and ticagrelor (initial dose of 180 mg and subsequent doses of 90 mg two times per day for 2 months), respectively. (A) Both groups demonstrated a decrease in Scr levels, which was significant in the observation group. (B) Both groups demonstrated a decrease in Cys-C levels, which was significant in the observation group. (C) Both groups demonstrated a decrease in β2-MG levels, which was significant in the observation group. The results are presented as the mean ± standard deviation, and * represents p < 0.05.

ST-segment elevation myocardial infarction, STEMI; Scr, serum creatinine; Cys-C, cystatin C; β2-MG, β2 macroglobulin.
that these were improved after treatment, with significant improvements observed in the observation group, indicating that the combination promotes cardiac vascular endothelial protection and cardiac ejection efficiency. The results of a previous study\textsuperscript{23} suggested that atorvastatin calcium tablets could effectively protect vascular

\begin{figure*}[h]
\centering
\includegraphics[width=\textwidth]{figure4}
\caption{ST2 and IL-33 levels before and after treatment in STEMI patients. The control group (n = 44) and observation group (n = 40) were given oral atorvastatin (80 mg before thrombolytic therapy and subsequent doses of 20 mg/day for 2 months) or a combination of atorvastatin and ticagrelor (initial dose of 180 mg and subsequent doses of 90 mg two times per day for 2 months), respectively. (A) Both groups demonstrated a decrease in ST2 levels, which was significant in the observation group. (B) Both groups demonstrated a decrease in IL-33 levels, which was significant in the observation group. The results are presented as the mean ± standard deviation, and * represents $p < 0.05$.}
\end{figure*}

\begin{table}[h]
\centering
\caption{Clinical effects [n (%)].}
\label{table3}
\begin{tabular}{lccc}
\hline
Group & Control Group (n = 44) & Observation Group (n = 40) & $\chi^2$ & $P$ \\
\hline
Markedly effective & 19 (43.18) & 27 (67.50) & – & – \\
Effective & 17 (38.64) & 11 (27.50) & – & – \\
Ineffective & 9 (20.45) & 2 (50.00) & – & – \\
Total effective rate & 35 (79.55) & 38 (95.00) & 4.397 & 0.036 \\
\hline
\end{tabular}
\end{table}

\begin{table}[h]
\centering
\caption{Adverse cardiovascular event incidences [n (%)].}
\label{table4}
\begin{tabular}{lccc}
\hline
Group & Control Group (n = 44) & Observation Group (n = 40) & $\chi^2$ & $P$ \\
\hline
Postinfarction angina pectoris & 3 (6.82) & 1 (2.50) & – & – \\
Congestive heart failure & 4 (9.09) & 1 (2.50) & – & – \\
Recurrent myocardial infarction & 3 (6.82) & 1 (2.50) & – & – \\
Cardiac death & 1 (2.27) & 0 & – & – \\
Total incidence of adverse cardiovascular events & 11 (25.00) & 3 (7.50) & 4.620 & 0.032 \\
\hline
\end{tabular}
\end{table}
endothelial function, inhibit atherosclerosis and intravascular plaque formation, and maintain cardiac systole and pumping function. Additionally, one study\textsuperscript{24} showed that ticagrelor could rapidly prevent platelet aggregation, which is the main cause of vascular endothelial and cardiomyocyte injury, and contribute to the recovery of cardiac vessels and cardiomyocytes. The myocardial infarct size in both groups was markedly reduced, with a significant reduction observed in the observation group, indicating that the combination of the two drugs results in a higher recovery efficiency and enhanced cardiac reperfusion than atorvastatin alone. A previous report\textsuperscript{25} proposed that ticagrelor accelerated the recovery of coronary blood flow, reduced the release of oxygen free radicals and injury due to oxidative stress, and contributed to the recovery of antioxidant function in the body. This further explains why the combination of the two drugs can enhance the efficacy of reperfusion and prevent myocardial infarction by protecting the cardiac ejection ability and reducing myocardial cell oxidation. Furthermore, Ser, Cys-C, and $\beta$2-MG levels were decreased after treatment, with a significant reduction observed in the observation group. A previous study suggested\textsuperscript{26} that patients treated with ticagrelor exhibited improvements in hemodynamics and cerebral blood volume, which was beneficial for the steady flow of blood in the kidneys, reduction of ischemic renal injury, and improvement of glomerular filtration rate and sodium excretion because of the diuretic function of this drug. In the present study, inflammatory parameters were also analyzed in the two groups. After treatment, ST2 and IL-33 levels were reduced in both groups, with a significant reduction observed in the observation group, demonstrating that the combination of the two drugs can more effectively reduce inflammation. Furthermore, a previous study\textsuperscript{27} reported that ticagrelor promoted myocardial cell repair and restored cardiac function via its inflammatory resistance and myocardial protection functions. For adverse reactions, the control group exhibited a higher total incidence of adverse cardiovascular events after treatment; however, no significant difference was noted in the total incidence of adverse reactions. These results indicate that the combination of the two drugs did not increase adverse effects but rather alleviated the severity of cardiovascular diseases, which was suggested to be correlated with the effect of the two drugs as a combination treatment on improving heart and renal functions and reducing inflammation.

In conclusion, atorvastatin and ticagrelor combination therapy demonstrated a good safety profile by recovering heart and renal functions, reducing inflammation, and stabilizing the condition of patients with STEMI. However, the present study had limitations. Specifically, minimal information was obtained regarding the effect of myocardial infarction severity on renal function and other factors that cause

| Group                      | Control Group (n = 44) | Observation Group (n = 40) | $\chi^2$ | P     |
|---------------------------|------------------------|---------------------------|---------|-------|
| Nausea                    | 2 (4.55)               | 2 (5.00)                  | –       | –     |
| Vomiting                  | 1 (2.27)               | 1 (2.50)                  | –       | –     |
| Abdominal discomfort      | 1 (2.27)               | 0                         | –       | –     |
| Total incidence of adverse reactions | 4 (9.09)               | 3 (7.50)                  | 0.069   | 0.792 |

Table 5. Total incidence of adverse reactions [n (%)].
changes in renal function. In addition, the exclusion criteria were insufficient and not clear enough when selecting study subjects. These questions should be prioritized and answered in future studies.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Li Zhang https://orcid.org/0000-0001-6431-5376

References

1. From AM, Best PJM, Lennon RJ, et al. Acute Myocardial Infarction Due to Left Circumflex Artery Occlusion and Significance of ST-Segment Elevation – American Journal of Cardiology. Am J Cardiol 2010; 106: 1081–1085. DOI: 10.1016/j.amjcard.2010.06.016.
2. Ozer MK, Sahna EM and Acet A. Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. Pharmacol Res 2002; 45: 257–263. DOI: 10.1006/phrs.2002.0965.
3. De Luca G, Suryapranata H, Ottervanger JP, et al. Impact of statin therapy at discharge on 1-year mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty. Atherosclerosis 2006; 189: 186–192. DOI: 10.1016/j.atherosclerosis.2005.11.028.
4. Chen CYJ, Yang TC, Chang C, et al. Homocysteine is a bystander for ST-segment elevation myocardial infarction: a case-control study. BMC Cardiovasc Disord 2018; 18: 33. DOI: 10.1186/s12872-018-0774-8.
5. Eagle KA, Nallamoorthy BK, Mehta RH, et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J 2008; 29: 609–617. DOI: 10.1093/eurheartj/ehn069.
6. Hamilton RJ, Keyles V and Banka SS. Synthetic Cannabinoid Abuse Resulting in ST-Segment Elevation Myocardial Infarction Requiring Percutaneous Coronary Intervention. J Emerg Med 2017; 52: 496–498. DOI: 10.1016/j.jemermed.2016.09.023.
7. Ghali WA, Donaldson CR, Knudtson ML, et al. Rising to the challenge: transforming the treatment of ST-segment elevation myocardial infarction. CMAJ 2003; 169: 35–37.
8. Katsiki N, Doumas M and Mikhailidis DP. Lipids, Statins and Heart Failure: An Update. Curr Pharm Des 2016; 22: 4796–4806. DOI: 10.2174/1381612822666160701073452.
9. Chang Y, Li Y, Ye N, et al. Atorvastatin protects the proliferative ability of human umbilical vein endothelial cells inhibited by angiotensin II by changing mitochondrial energy metabolism. Int J Mol Med 2018; 41: 33–42. DOI: 10.3892/ijmm.2017.3200.
10. Sugidachi A, Ohno K, Ogawa T, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol 2013; 169: 82–89. DOI: 10.1111/bph.12108.
11. Timoteo AT, Fiarresga A, Feliciano J, et al. The prognostic impact of renal failure in patients with ST-segment elevation acute myocardial infarction. Kardiol Pol 2005; 63: 373.
12. Zykov MV, Barbarash OL, Kashtalap VV, et al. Interleukin-12 serum level has prognostic value in patients with ST-segment elevation myocardial infarction. Heart Lung 2016; 45: 336–340. DOI: 10.1016/j.hrtlng.2016.03.007.
13. Simprini LA. Cardiac CT Imaging: Diagnosis of Cardiovascular Disease, 2nd edition. J Cardiovasc Comput Tomogr 2011; 5: 129–129.
14. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other
Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). *Eur Heart J* 2007; 28: 2375–2414. DOI: 10.1093/eurheartj/ehm316.

15. Zimmet J, Wu KC, Geerse DA, et al. Comparison between contrast-enhanced magnetic resonance imaging and Selvester QRS scoring system in estimating changes in infarct size between the acute and chronic phases of myocardial infarction. *Am Noninvasive Electrocardiol* 2009; 14: 360–365. DOI: 10.1111/j.1542-474X.2009.00327.x.

16. Taher T, Fu Y, Wagner GS, et al. Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. *J Am Coll Cardiol* 2004; 44: 38–43. DOI: 10.1016/j.jacc.2004.03.041.

17. Nishiguchi T, Tanaka A, Taruya A, et al. Local Matrix Metalloproteinase 9 Level Determines Early Clinical Presentation of ST-Segment-Elevation Myocardial Infarction. *Arterioscler Thromb Vasc Biol* 2016; 36: 2460–2467. DOI: 10.1161/ATVBAHA.116.308099.

18. Al-Zakwani I, Ali A, Zubaid M, et al. Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East. *J Thromb Thrombolysis* 2012; 33: 280–286. DOI: 10.1007/s1239-012-0698-6.

19. Zhou H, Xie Y, Baloch Z, et al. The effect of atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (HMG-CoA), on the prevention of osteoporosis in ovariectomized rabbits. *J Bone Miner Metab* 2017; 35: 245–254. DOI: 10.1007/s00774-016-0750-2.

20. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009; 361: 1045–1057. DOI: 10.1056/NEJMoa0904327.

21. Lott JM, Sumpter TL and Turnquist HR. New dog and new tricks: evolving roles for IL-33 in type 2 immunity. *J Leukoc Biol* 2015; 97: 1037–1048. DOI: 10.1189/jlb.3RI1214-595R.

22. Aoki S, Hayakawa M, Ozaki H, et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. *Mol Cell Biochem* 2010; 335: 75–81. DOI: 10.1007/s11010-009-0244-9.

23. Wei YN and Zhou HY. Preventive effects of different doses of atorvastatin calcium on cerebral infarction in patients with carotid atherosclerosis. *Sichuan Med J* 2013; 34: 536–537.

24. He M, Li D, Zhang Y, et al. Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease. *Platelets* 2019; 30: 752–761. DOI: 10.1080/09537104.2018.1513479.

25. Xie XR and Pu Y. Effect of loading-dose ticagrelor on coronary blood flow, left ventricular remodeling and myocardial enzyme spectrum in patients with acute myocardial infarction after interventional therapy. *J Hainan Med Univ* 2016; 22: 17–20.

26. Teng R and Butler K. Safety, tolerability, pharmacokinetics and pharmacodynamics of high single-ascending doses of ticagrelor in healthy volunteers. *Int J Clin Pharmacol Ther* 2013; 51: 795–806. DOI: 10.5414/CP201903.

27. Cao L and Bian YF. Effect of ticagrelor on serum uric acid level and its anti-inflammatory effect in acute coronary syndrome patients after PCI. *Chin J Hospital Pharm* 2017; 37: 1498–1501.